<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anticoagulation for the initial treatment of venous thromboembolism in people with cancer - Kahale, LA - 2021 | Cochrane Library</title> <meta content="Anticoagulation for the initial treatment of venous thromboembolism in people with cancer - Kahale, LA - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006649.pub8/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anticoagulation for the initial treatment of venous thromboembolism in people with cancer - Kahale, LA - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006649.pub8/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006649.pub8" name="dc.identifier" scheme="DOI"/> <meta content="Anticoagulation for the initial treatment of venous thromboembolism in people with cancer" name="citation_title"/> <meta content="Lara A Kahale" name="citation_author"/> <meta content="American University of Beirut" name="citation_author_institution"/> <meta content="Charbel F Matar" name="citation_author"/> <meta content="University of Connecticut School of Medicine" name="citation_author_institution"/> <meta content="Maram B Hakoum" name="citation_author"/> <meta content="Cornerstone Care Teaching Health Center" name="citation_author_institution"/> <meta content="Ibrahim G Tsolakian" name="citation_author"/> <meta content="Univeristy of Toledo" name="citation_author_institution"/> <meta content="Victor ED Yosuico" name="citation_author"/> <meta content="Buffalo Medical Group" name="citation_author_institution"/> <meta content="Irene Terrenato" name="citation_author"/> <meta content="IRCCS Regina Elena National Cancer Institute" name="citation_author_institution"/> <meta content="Francesca Sperati" name="citation_author"/> <meta content="IRCCS Regina Elena National Cancer Institute" name="citation_author_institution"/> <meta content="Maddalena Barba" name="citation_author"/> <meta content="IRCCS Regina Elena National Cancer Institute" name="citation_author_institution"/> <meta content="Holger SchÃ¼nemann" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Elie A Akl" name="citation_author"/> <meta content="American University of Beirut Medical Center" name="citation_author_institution"/> <meta content="ea32@aub.edu.lb" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD006649.pub8" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/12/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006649.pub8/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006649.pub8/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006649.pub8/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [adverse effects]; Heparin [adverse effects]; Heparin, Low-Molecular-Weight [adverse effects]; *Neoplasms [complications]; *Venous Thromboembolism [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006649.pub8&amp;doi=10.1002/14651858.CD006649.pub8&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006649\x2epub8\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006649\x2epub8\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","pt","ko","ms","ja","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006649.pub8",title:"Anticoagulation for the initial treatment of venous thromboembolism in people with cancer",firstPublishedDate:"Dec 8, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006649.pub8&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006649.pub8';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> EspaÃ±ol </option> <option class="content-language-option" data-languagecode="fa" value="fa"> ÙØ§Ø±Ø³Û </option> <option class="content-language-option" data-languagecode="fr" value="fr"> FranÃ§ais </option> <option class="content-language-option" data-languagecode="hi" value="hi"> à¤¹à¤¿à¤¨à¥à¤¦à¥ </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> æ¥æ¬èª </option> <option class="content-language-option" data-languagecode="ko" value="ko"> íêµ­ì´ </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> PortuguÃªs </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Ð ÑÑÑÐºÐ¸Ð¹ </option> <option class="content-language-option" data-languagecode="ro" value="ro"> RomÃ¢nÄ </option> <option class="content-language-option" data-languagecode="ta" value="ta"> à®¤à®®à®¿à®´à¯ </option> <option class="content-language-option" data-languagecode="th" value="th"> à¸ à¸²à¸©à¸²à¹à¸à¸¢ </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> ç¹é«ä¸­æ </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> ç®ä½ä¸­æ </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006649.pub8/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006649.pub8/full/es"> EspaÃ±ol </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006649.pub8%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006649.PUB8" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;ÚÚ©ÛØ¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì´ë¡&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;æè¦&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en tÃ©rminos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Ø®ÙØ§ØµÙ Ø¨Ù Ø²Ø¨Ø§Ù Ø³Ø§Ø¯Ù&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;RÃ©sumÃ© simplifiÃ©&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;ä¸è¬èªè¨³&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;ì¬ì´ ë§ ìì½&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym jÄzykiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Ð ÐµÐ·ÑÐ¼Ðµ Ð½Ð° Ð¿ÑÐ¾ÑÑÐ¾Ð¼ ÑÐ·ÑÐºÐµ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;ç®è¯­æ¦è¦&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;æ·ºé¡¯ææçå£èªçµè«&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006649.pub8/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006649.PUB8" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006649.pub8/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006649.pub8/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views:Â </span> <span>2719 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006649.pub8" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-sec-0071"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-sec-0065"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/appendices#CD006649-sec-0076"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/table_n/CD006649StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/table_n/CD006649StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright Â© 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anticoagulation for the initial treatment of venous thromboembolism in people with cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0004">Lara A Kahale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0005">Charbel F Matar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0006">Maram B Hakoum</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0007">Ibrahim G Tsolakian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0008">Victor ED Yosuico</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0009">Irene Terrenato</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0010">Francesca Sperati</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0011">Maddalena Barba</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0012">Holger SchÃ¼nemann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information#CD006649-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>Elie A Akl</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information/en#CD006649-sec-0081">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 December 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006649.pub8">https://doi.org/10.1002/14651858.CD006649.pub8</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006649-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006649-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006649-abs-0017">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006649-abs-0012">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006649-abs-0015">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006649-abs-0008">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006649-abs-0003">ç®ä½ä¸­æ</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006649-abs-0001" lang="en"> <section id="CD006649-sec-0001"> <h3 class="title" id="CD006649-sec-0001">Background</h3> <p>Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE. </p> </section> <section id="CD006649-sec-0002"> <h3 class="title" id="CD006649-sec-0002">Objectives</h3> <p>To compare the efficacy and safety of three types of parenteral anticoagulants (i.e. fixedâdose low molecular weight heparin (LMWH), adjustedâdose unfractionated heparin (UFH), and fondaparinux) for the initial treatment of VTE in people with cancer. </p> </section> <section id="CD006649-sec-0003"> <h3 class="title" id="CD006649-sec-0003">Search methods</h3> <p>We performed a comprehensive search in the following major databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (via Ovid) and Embase (via Ovid). We also handsearched conference proceedings, checked references of included studies, and searched for ongoing studies. This update of the systematic review is based on the findings of a literature search conducted on 14 August 2021. </p> </section> <section id="CD006649-sec-0004"> <h3 class="title" id="CD006649-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) assessing the benefits and harms of LMWH, UFH, and fondaparinux in people with cancer and objectively confirmed VTE. </p> </section> <section id="CD006649-sec-0005"> <h3 class="title" id="CD006649-sec-0005">Data collection and analysis</h3> <p>Using a standardised form, we extracted data â in duplicate â on study design, participants, interventions, outcomes of interest, and risk of bias. Outcomes of interest included allâcause mortality, symptomatic VTE, major bleeding, minor bleeding, postphlebitic syndrome, quality of life, and thrombocytopenia. We assessed the certainty of evidence for each outcome using the GRADE approach. </p> </section> <section id="CD006649-sec-0006"> <h3 class="title" id="CD006649-sec-0006">Main results</h3> <p>Of 11,484 identified citations, 3073 were unique citations and 15 RCTs fulfilled the eligibility criteria, none of which were identified in the latest search. These trials enrolled 1615 participants with cancer and VTE: 13 compared LMWH with UFH; one compared fondaparinux with UFH and LMWH; and one compared dalteparin with tinzaparin, two different types of low molecular weight heparin. </p> <p>The metaâanalyses showed that LMWH may reduce mortality at three months compared to UFH (risk ratio (RR) 0.66, 95% confidence interval (CI) 0.40 to 1.10; risk difference (RD) 57 fewer per 1000, 95% CI 101 fewer to 17 more; low certainty evidence) and may reduce VTE recurrence slightly (RR 0.69, 95% CI 0.27 to 1.76; RD 30 fewer per 1000, 95% CI 70 fewer to 73 more; low certainty evidence). There were no data available for bleeding outcomes, postphlebitic syndrome, quality of life, or thrombocytopenia. </p> <p>The study comparing fondaparinux with heparin (UFH or LMWH) found that fondaparinux may increase mortality at three months (RR 1.25, 95% CI 0.86 to 1.81; RD 43 more per 1000, 95% CI 24 fewer to 139 more; low certainty evidence), may result in little to no difference in recurrent VTE (RR 0.93, 95% CI 0.56 to 1.54; RD 8 fewer per 1000, 95% CI 52 fewer to 63 more; low certainty evidence), may result in little to no difference in major bleeding (RR 0.82, 95% CI 0.40 to 1.66; RD 12 fewer per 1000, 95% CI 40 fewer to 44 more; low certainty evidence), and probably increases minor bleeding (RR 1.53, 95% CI 0.88 to 2.66; RD 42 more per 1000, 95% CI 10 fewer to 132 more; moderate certainty evidence). There were no data available for postphlebitic syndrome, quality of life, or thrombocytopenia. </p> <p>The study comparing dalteparin with tinzaparin found that dalteparin may reduce mortality slightly (RR 0.86, 95% CI 0.43 to 1.73; RD 33 fewer per 1000, 95% CI 135 fewer to 173 more; low certainty evidence), may reduce recurrent VTE (RR 0.44, 95% CI 0.09 to 2.16; RD 47 fewer per 1000, 95% CI 77 fewer to 98 more; low certainty evidence), may increase major bleeding slightly (RR 2.19, 95% CI 0.20 to 23.42; RD 20 more per 1000, 95% CI 14 fewer to 380 more; low certainty evidence), and may reduce minor bleeding slightly (RR 0.82, 95% CI 0.30 to 2.21; RD 24 fewer per 1000, 95% CI 95 fewer to 164 more; low certainty evidence). There were no data available for postphlebitic syndrome, quality of life, or thrombocytopenia. </p> </section> <section id="CD006649-sec-0007"> <h3 class="title" id="CD006649-sec-0007">Authors' conclusions</h3> <p>Low molecular weight heparin (LMWH) is probably superior to UFH in the initial treatment of VTE in people with cancer. Additional trials focusing on patientâimportant outcomes will further inform the questions addressed in this review. The decision for a person with cancer to start LMWH therapy should balance the benefits and harms and consider the person's values and preferences. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006649-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006649-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006649-abs-0018">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006649-abs-0013">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006649-abs-0016">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006649-abs-0011">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006649-abs-0009">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006649-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006649-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006649-abs-0007">PortuguÃªs</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006649-abs-0006">Ð ÑÑÑÐºÐ¸Ð¹</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006649-abs-0004">ç®ä½ä¸­æ</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006649-abs-0005">ç¹é«ä¸­æ</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006649-abs-0002" lang="en"> <h3>Blood thinners for the initial treatment of blood clots in people with cancer</h3> <p><b>Background</b><br/>People with cancer are at increased risk of blood clots. The blood thinner (anticoagulant) administered in the first few days after identifying a blood clot can consist of unfractionated heparin (infused through a vein), low molecular weight heparin (LMWH, injected under the skin once or twice per day; dalteparin and tinzaparin are two different types of low molecular weight heparin), or fondaparinux (injected under the skin once daily). These blood thinners may have different effectiveness and safety profiles. </p> <p><b>Study characteristics</b><br/>We searched scientific databases for clinical trials comparing different blood thinners in people with cancer with a confirmed diagnosis of clots in the limbs or in the lungs. We included trials of adults and children with either solid tumours or blood cancer, irrespective of the type of cancer treatment. The trials looked at death, recurrent blood clots, and bleeding. The evidence is current to August 2021. </p> <p><b>Key results</b><br/>We identified 15 studies in total. Data from five studies suggested that the LMWH may reduce death at three months compared to UFH, and may reduce recurrent clots slightly. We found no data to compare the effect of these two medications on bleeding outcomes. Also, we found that fondaparinux may increase death at three months, may result in little to no difference in recurrent clots and major bleeding, and probably increases minor bleeding. Also, the current evidence found that dalteparin, a type of LMWH, may reduce death slightly, may reduce recurrent clots, may increase major bleeding slightly, and may reduce minor bleeding slightly. </p> <p><b>Certainty of the evidence</b><br/>We judged the certainty of evidence for low molecular weight heparin versus unfractionated heparin to be low for all assessed outcomes; for fondaparinux versus heparin to be low certainty, except for minor bleeding which was moderate certainty; and for tinzaparin versus dalteparin, to be low certainty. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006649-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006649-sec-0071"></div> <h3 class="title" id="CD006649-sec-0072">Implications for practice</h3> <section id="CD006649-sec-0072"> <p>Low molecular weight heparin (LMWH) is probably superior to unfractionated heparin (UFH) in reducing mortality in the initial treatment of venous thromboembolism (VTE) in people with cancer. Also, there are additional advantages of LMWH related to subcutaneous administration and outpatient management (<a href="./references#CD006649-bbs2-0130" title="O'BrienB , LevineM , WillanA , GoereeR , HaleyS , BlackhouseG , GentM . Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Archives of Internal Medicine1999;159(19):2298-304.">O'Brien 1999</a>; <a href="./references#CD006649-bbs2-0131" title="OthienoR , Abu AffanM , OkpoE . Home versus in-patient treatment for deep vein thrombosis. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD003076. [DOI: 10.1002/14651858.CD003076.pub2]">Othieno 2007</a>). </p> <p>The decision for a person with cancer with VTE to start heparin therapy should balance the benefits and harms, and should integrate the person's values and preferences (<a href="./references#CD006649-bbs2-0115" title="HaynesRB , DevereauxPJ , GuyattGH . Clinical expertise in the era of evidence-based medicine and patient choice. Vox Sanguinis2002;83(Suppl 1):383-6.">Haynes 2002</a>). </p> </section> <h3 class="title" id="CD006649-sec-0073">Implications for research</h3> <section id="CD006649-sec-0073"> <p>There is a need to conduct trials comparing anticoagulants in the initial treatment of VTE that are restricted to people with cancer. Researchers should consider making the raw data of randomised controlled trials available for individual participant data metaâanalysis. In addition, as recognised by Cochrane, addressing all important outcomes, including harm, is of great importance in making evidenceâbased healthcare decisions. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006649-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006649-sec-0008"></div> <div class="table" id="CD006649-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Low molecular weight heparin compared to unfractionated heparin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Low molecular weight heparin compared to unfractionated heparin for initial treatment in people with cancer with VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cancer with venous thromboembolism (VTE)<br/><b>Setting:</b> inpatient/outpatient<br/><b>Intervention:</b> low molecular weight heparin (LMWH)<br/><b>Comparison:</b> unfractionated heparin (UFH) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/>Followâup</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with UFH</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>418<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.40 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 fewer per 1000<br/>(101 fewer to 17 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent VTE<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>422<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/>(0.27 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 fewer per 1000<br/>(70 fewer to 73 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor bleeding â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postphlebitic syndrome â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (101 fewer per 1000) and potential harm (17 more per 1000), including 59 events in total.<br/><sup>b</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (70 fewer per 1000) and potential harm (73 more per 1000), including 34 events in total. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006649-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Fondaparinux compared to heparin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Fondaparinux compared to heparin for initial treatment in people with cancer with VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cancer with VTE<br/><b>Setting:</b> inpatient/outpatient<br/><b>Intervention:</b> fondaparinux<br/><b>Comparison:</b> heparin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/>Followâup</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with heparin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with fondaparinux</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>477<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.25<br/>(0.86 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 more per 1000<br/>(24 fewer to 139 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent VTE<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>477<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/>(0.56 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/>(52 fewer to 63 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>477<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.40 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 fewer per 1000<br/>(40 fewer to 44 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>477<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.53<br/>(0.88 to 2.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 more per 1000<br/>(10 fewer to 132 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postphlebitic syndrome â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (24 fewer per 1000) and potential harm (139 more per 1000), including only 92 events in total.<br/><sup>b</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (52 fewer per 1000) and potential harm (63 moreÂ per 1000 ), including only 54 events in total.<br/><sup>c</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (40 fewer per 1000) and potential harm (44 moreÂ per 1000 ), including only 29 events in total.<br/><sup>d</sup>Downgraded by one level due to serious imprecision. Confidence interval suggests both potential no effect (10 fewer per 1000) and potential harm (132 moreÂ per 1000 ), including only 48 events in total. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006649-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Dalteparin compared to tinzaparin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Dalteparin compared to tinzaparin for initial treatment in people with cancer with VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> initial treatment in people with cancer with VTE<br/><b>Setting:</b> inpatient/outpatient<br/><b>Intervention:</b> dalteparin<br/><b>Comparison:</b> tinzaparin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/>Followâup</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with tinzaparin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with dalteparin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>113<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.43 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/>(135 fewer to 173 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent VTE<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>113<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44<br/>(0.09 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 fewer per 1000<br/>(77 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>113<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.19<br/>(0.20 to 23.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 more per 1000<br/>(14 fewer to 380 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>113<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.30 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 fewer per 1000<br/>(95 fewer to 164 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postphlebitic syndrome â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (135 fewer per 1000 ) and potential harm (173 more per 1000 ), including 25 events among included participants.<br/><sup>b</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (77 fewer per 1000 ) and potential harm (98 more per 1000 ), including 7 events among included participants.<br/><sup>c</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (14 fewer per 1000 ) and potential harm (380 moreÂ per 1000 ), including 3 events among included participants.<br/><sup>d</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (95 fewer per 1000 ) and potential harm (164 more per 1000 ), including 14 events among included participants. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006649-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006649-sec-0009"></div> <p>Please refer to the glossary for the definitions of technical terms (<a href="#CD006649-tbl-0004">Table 1</a>). </p> <div class="table" id="CD006649-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span>Â <span class="table-title">Glossary</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A priori</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Made before or without exam; not supported by factual study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assisting in the amelioration or cure of disease.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Process of hindering the clotting of blood, especially by treatment with an anticoagulant.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antithrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Used against or tending to prevent thrombosis (clotting).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotting.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis (DVT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Condition marked by the formation of a thrombus within a deep vein (such as of the leg or pelvis) that may be asymptomatic or be accompanied by symptoms (such as swelling and pain), and that is potentiallyâlife threatening if dislodgment of the thrombus results in pulmonary embolism. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fondaparinux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dalteparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemostatic system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>System that shortens the clotting time of blood and stops bleeding.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by preventing the formation of fibrin. Two forms of heparin that are used as anticoagulant medications are: unfractionated heparin (UFH) and low molecular weight heparin (LMWH). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality or state of being heterogeneous, i.e. incongruous. Statistical technique to check whether study results are consistent. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercoagulable state</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>State of excessive affinity to clotting.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impedance plethysmography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Technique that measures the change in blood volume (venous blood volume as well as the pulsation of the arteries) for a specific body segment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kappa statistic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measure of degree of nonrandom agreement between observers, measurements of a specific categorical variable, or both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spread of cancer cells from the initial or primary site of disease to another part of the body. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parenteral nutrition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Practice of feeding a person intravenously, circumventing the gastrointestinal tract.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary embolism (PE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embolism of a pulmonary artery or 1 of its branches that is produced by foreign matter and most often a blood clot originating in a vein of the leg or pelvis and that is marked by laboured breathing, chest pain, fainting, rapid heart rate, cyanosis, shock, and sometimes death. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Persistent decrease in the number of blood platelets that is often associated with haemorrhagic conditions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formation or presence of a blood clot within a blood vessel.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin K antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medications that are used for anticoagulation. Warfarin is a vitamin K antagonist. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication that is a vitamin K antagonist used for anticoagulation.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ximelagatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication.</p> </td> </tr> </tbody> </table> </div> <section id="CD006649-sec-0010"> <h3 class="title" id="CD006649-sec-0010">Description of the condition</h3> <p>People with cancer are at increased risk of venous thromboembolism (VTE) by fourâ to sixâfold (<a href="./references#CD006649-bbs2-0116" title="HeitJA , SilversteinMD , MohrDN , PettersonTM , O'FallonWM , Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Archives of Internal Medicine2000;160(6):809-15.">Heit 2000</a>), with thromboembolic events being the second leading cause of death (<a href="./references#CD006649-bbs2-0126" title="KhoranaAA , FrancisCW , CulakovaE , KudererNM , LymanGH . Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis : JTH2007;5(3):632-4.">Khorana 2007</a>). Cancerâassociated VTE development is affected by multiple factors, including individuals' comorbidity or comorbidities, tumour type and site of origin, treatment administered, and individuals' biomarkers (<a href="./references#CD006649-bbs2-0106" title="AyC , PabingerI , CohenAT . Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thrombosis and Haemostasis2017;117:219-230.">Ay 2017</a>). In addition, therapeutic interventions such as chemotherapy, hormonal therapy, indwelling central venous catheters, and more recently immunotherapy treatments, either alone or combined, increase the risk of VTE (<a href="./references#CD006649-bbs2-0116" title="HeitJA , SilversteinMD , MohrDN , PettersonTM , O'FallonWM , Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Archives of Internal Medicine2000;160(6):809-15.">Heit 2000</a>; <a href="./references#CD006649-bbs2-0136" title="RoopkumarJ , KimAS , BickyT , HobbsBP , KhoranaAA . Venous thromboembolism in cancer patients receiving immunotherapy. Blood2018;132:2510.">Roopkumar 2018</a>). Moreover, compared to the general population, VTE recurrence is higher in people with cancer after their first VTE, with an overall incidence rate for recurrence of 9.6 per 100 personâyears and a peak of 22.1 in the first six months after diagnosis (<a href="./references#CD006649-bbs2-0107" title="CohenAT , KatholingA , RietbrockS , BamberL , MartinezC . Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. Thrombosis and Haemostasis2017;26(1):57-65.">Cohen 2017</a>). Similarly, people undergoing surgery for cancer have a higher risk of VTE than people undergoing surgery for diseases other than cancer (<a href="./references#CD006649-bbs2-0113" title="GallusAS . Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thrombosis and Haemostasis1997;78(1):126-32.">Gallus 1997</a>; <a href="./references#CD006649-bbs2-0124" title='KakkarVV , HoweCT , NicolaidesAN , RenneyJT , ClarkeMB . Deep vein thrombosis of the leg. Is there a "high risk" group?American Journal of Surgery1970;120(4):527-30.'>Kakkar 1970</a>). People with cancer and VTE have a higher risk of death than people with cancer alone or VTE alone (<a href="./references#CD006649-bbs2-0127" title="LevitanN , DowlatiA , RemickSC , TahsildarHI , SivinskiLD , BeythR . Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine1999;78(5):285-91.">Levitan 1999</a>; <a href="./references#CD006649-bbs2-0139" title="SorensenHT , MellemkjaerL , OlsenJH , BaronJA . Prognosis of cancers associated with venous thromboembolism. New England Journal of Medicine2000;343(25):1846-50.">Sorensen 2000</a>). </p> <p>People receiving cancer therapy reach a heightened hypercoagulable state, which may alter the response to anticoagulant treatment and the risk of bleeding. These people are also more likely to develop major bleeding, with an annual risk of 12% to 13%, a twoâ to sixâfold risk increase (<a href="./references#CD006649-bbs2-0122" title="HuttenBA , PrinsMH , GentM , GinsbergJ , TijssenJG , BullerHR . Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. Journal of Clinical Oncology2000;18(17):3078-83.">Hutten 2000</a>; <a href="./references#CD006649-bbs2-0133" title="PrandoniP , LensingAW , PiccioliA , BernardiE , SimioniP , GirolamiB , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood2002;100(10):3484-8.">Prandoni 2002</a>). The increased tendency for bleeding may be related to cancerâ or treatmentâassociated thrombocytopenia, disseminated intravascular coagulation, or production of fibrinolytic factors by tumour cells (<a href="./references#CD006649-bbs2-0129" title="MosarlaR , VaduganathanM , QamarQ , MoslehiJ , PiazzaG , GiuglianoRP . Anticoagulation strategies in patients with cancer. Journal of the American College of Cardiology2019;73(11):1336-1349.">Mosarla 2019</a>). All of these factors may lead to an increase in morbidity, mortality, and costs associated with VTE management in people with cancer (<a href="./references#CD006649-bbs2-0128" title="LymanG , CulakovaE , PoniewierskiM , KudererN . Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thrombosis Research2018;164:112-118.">Lyman 2018</a>). </p> </section> <section id="CD006649-sec-0011"> <h3 class="title" id="CD006649-sec-0011">Description of the intervention</h3> <p>Heparin, low molecular weight heparins (LMWHs), fondaparinux, and danaparoidÂ  (another type of anticoagulant) do not have intrinsic anticoagulant activity but potentiate the activity of antithrombin III in inhibiting activated coagulation factors. These agents constitute indirect anticoagulants as their activity is mediated by plasma cofactors. Recombinant hirudin, bivalirudin, and argatroban directly inhibit thrombin and are classified as direct anticoagulants (<a href="./references#CD006649-bbs2-0121" title="HirshJ , BauerKA , DonatiMB , GouldM , SamamaMM , WeitzJI . Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest2008;133 Suppl:141-59.">Hirsh 2008</a>). Heparin and its low molecular weight derivatives are not absorbed orally and must be administered parenterally by intravenous (IV) infusion or subcutaneous (SC) injection (<a href="./references#CD006649-bbs2-0120" title="HirshJ . Low molecular weight heparin. Thrombosis and Haemostasis1993;70(1):204-7.">Hirsh 1993</a>). </p> </section> <section id="CD006649-sec-0012"> <h3 class="title" id="CD006649-sec-0012">How the intervention might work</h3> <p>In the initial treatment of VTE, LMWHs and unfractionated heparin (UFH) might have a different comparative efficacy in people with cancer and in people without cancer. Moreover, several clinical trials have proven that anticoagulants may have a positive impact through antithrombotic effect and possibly antitumour effect (<a href="./references#CD006649-bbs2-0132" title="ParkJC , PratzCF , TesfayeA , BrodskyRA , AntonarakisES . The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer. Clinical Genitourinary Cancer2015;13(1):32-8.">Park 2015</a>). </p> <p>Subgroup analyses of a Cochrane systematic review that includes 24 studies, showed that, in people without cancer, there was no statistically significant difference between the effects of LMWH and UFH on overall mortality (odds ratio (OR) 0.84, 95% confidence interval (CI) 0.70 to 1.01; P = 0.07; moderate quality evidence) (<a href="./references#CD006649-bbs2-0135" title="RobertsonL , JonesLE . Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD001100. [DOI: 10.1002/14651858.CD001100.pub4]">Robertson 2017</a>). </p> <p>Multiple guidelines exist for the initial anticoagulation management of cancerâassociated VTE (<a href="./references#CD006649-bbs2-0140" title="StreiffMB , AbutalibSA , FargeD , MurphyM , ConnorsJM , PiazzaG . Update on guidelines for the management of cancer-associated thrombosis. Oncologist2021;26:e24-e40.">Streiff 2021</a>). Regarding parenteral agents, the American Society of Clinical Oncology (ASCO) guidelines recommend LMWH over UFH for people with good renal function (<a href="./references#CD006649-bbs2-0125" title="KeyNS , KhoranaAA , KudererNM . Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guidelines update. Journal of Clinical Oncology2020;38:496-520.">Key 2020</a>). The International Society of Thrombosis and Hemostasis (ISTH) recommend individualised treatment regimens but suggest the use of LMWH for the initial treatment of VTE in people with high risk for bleeding (<a href="./references#CD006649-bbs2-0110" title="Di NisioM , CarrierM , LymanGH , Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of ISTH. Journal of Thrombosis and Haemostasis : JTH2014;12:1746-1749.">Di Nisio 2014</a>). The National Comprehensive Cancer Network (NCCN) recommend initial anticoagulation with parenteral LMWH for at least five days before considering oral anticoagulant agents. Initial anticoagulation may involve LMWH, UFH, fondaparinux, and heparin. The continuous and growing evidence informing practice has led to the publication of multiple systematic reviews and recommendations. </p> </section> <section id="CD006649-sec-0013"> <h3 class="title" id="CD006649-sec-0013">Why it is important to do this review</h3> <p>The previous update of this review, <a href="./references#CD006649-bbs2-0145" title="HakoumMB , KahaleLA , TsolakianIG , MatarCF , YosuicoVE , TerrenatoI , et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database of Systematic Reviews2018, Issue 1. Art. No: CD006649. [DOI: 10.1002/14651858.CD006649.pub7]">Hakoum 2018</a>, was ranked fifth in the top 10 reviews in the Cochrane Gynaecological, Neuroâoncology and Orphan Cancer Group informing nine guidelines. The last search was run on 14 January 2018 and therefore required updating (14 August 2021). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006649-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006649-sec-0014"></div> <p>To compare the efficacy and safety of three types of parenteral anticoagulants (i.e. fixedâdose low molecular weight heparin (LMWH), adjustedâdose unfractionated heparin (UFH), and fondaparinux) for the initial treatment of VTE in people with cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006649-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006649-sec-0015"></div> <section id="CD006649-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006649-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD006649-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants with cancer and a confirmed diagnosis of VTE (acute deep venous thrombosis (DVT) or pulmonary embolism (PE)). Participants could have been of any age group (including children) with either solid or haematologic cancer, and at any stage of their cancer, irrespective of the type of cancer therapy. </p> </section> <section id="CD006649-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Experimental arms consisted of initial parenteral anticoagulation (typically the first 5 to 10 days) with: </p> <p> <ul id="CD006649-list-0001"> <li> <p>LMWHs (e.g. dalteparin, tinzaparin, Fragmin);</p> </li> <li> <p>UFHs (e.g. Calciparine, multiparin, novoheparin);</p> </li> <li> <p>fondaparinux (e.g. Arixtra).</p> </li> </ul> </p> <p>We were interested in comparisons of any combination of the three management options listed above. </p> <p>We excluded studies in which thrombolytic therapy (e.g. streptokinase) was part of the intervention. The protocol should have planned to provide evidence concerning all other coâinterventions (e.g. chemotherapy) similarly. </p> </section> <section id="CD006649-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD006649-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006649-list-0002"> <li> <p>Allâcause mortality</p> </li> </ul> </p> </section> <section id="CD006649-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006649-list-0003"> <li> <p>Symptomatic recurrent DVT; events had to be diagnosed using at least one of the following objective diagnostic tests: venography, <sup>125</sup>Iâfibrinogen uptake test, impedance plethysmography, or Doppler ultrasound. </p> </li> <li> <p>Symptomatic recurrent PE; events had to be diagnosed using at least one of the following objective diagnostic tests: pulmonary perfusion or ventilation scans, computed tomography, pulmonary angiography, or autopsy. </p> </li> <li> <p>Major bleeding: we accepted the authors' definitions of major bleeding.</p> </li> <li> <p>Minor bleeding: we accepted the authors' definitions of minor bleeding.</p> </li> <li> <p>Postphlebitic syndrome</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Thrombocytopenia</p> </li> </ul> </p> <p>We assessed the primary and secondary outcomes up to three months after the initiation of treatment for VTE. </p> </section> </section> </section> <section id="CD006649-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006649-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The search was part of a comprehensive search for studies of anticoagulation in people with cancer. We conducted comprehensive searches on 14 August 2021, following the original electronic searches performed in January 2007, February 2010, February 2013, and January 2018. We electronically searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (via Ovid, starting 1946), and Embase (starting 1980; accessed via Ovid). The search strategies combined terms for anticoagulants, terms for cancer, and a search filter for RCTs. We used no language restrictions. We list the full search strategies for each of the electronic databases in <a href="./appendices#CD006649-sec-0077">Appendix 1</a>. </p> </section> <section id="CD006649-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched the conference proceedings of the American Society of Clinical Oncology (ASCO, from 1982 up to February 2021) and the American Society of Hematology (ASH, starting with its 2003 issue up to 14 August 2021). We also searched <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and <a href="http://www.who.int/ictrp/search/en/" target="_blank">World Health Organization (WHO) International Clinical Trials Registry Platform</a> for ongoing studies. We reviewed the reference lists of papers included in this review and of other relevant systematic reviews. In addition, we contacted experts in the field to check for unpublished and ongoing trials. </p> </section> </section> <section id="CD006649-sec-0026"> <h3 class="title" id="CD006649-sec-0026">Data collection and analysis</h3> <section id="CD006649-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Four pairs of review authors (LAK, CM, MH, IGT, VY, IT, FS, MB) independently screened the title and abstract of identified article citations for potential eligibility. We retrieved the full texts of articles judged potentially eligible by at least one review author. The review authors then independently screened the fullâtext articles for eligibility using a standardised form with explicit inclusion and exclusion criteria. The review authors resolved any disagreements concerning eligibility by discussion or by consulting a third review author. </p> </section> <section id="CD006649-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>The review authors independently extracted data from each included study and resolved their disagreements by discussion. We aimed to collect data related to the following. </p> <section id="CD006649-sec-0029"> <h5 class="title">Participants</h5> <p> <ul id="CD006649-list-0004"> <li> <p>Demographic characteristics (e.g. age, sex)</p> </li> <li> <p>Cancer characteristics (e.g. histological type, site of origin, stage at diagnosis, time since diagnosis, estimated life expectancy, current cancer treatments, performance status) </p> </li> <li> <p>Whether participants had DVT, PE, or both</p> </li> <li> <p>Number of participants in each treatment arm</p> </li> <li> <p>Number of participants randomised to each study arm</p> </li> <li> <p>Number of participants followed up in each study arm</p> </li> <li> <p>Number of participants who discontinued intervention in each arm</p> </li> </ul> </p> </section> <section id="CD006649-sec-0030"> <h5 class="title">Interventions</h5> <p> <ul id="CD006649-list-0005"> <li> <p>Type of anticoagulant (e.g. LMWH, UFH, fondaparinux)</p> </li> <li> <p>Dosage</p> </li> <li> <p>Administration schedule of the anticoagulants</p> </li> <li> <p>Duration of treatment</p> </li> <li> <p>Coâinterventions, including radiation therapy or systemic therapy (type and duration)</p> </li> </ul> </p> </section> <section id="CD006649-sec-0031"> <h5 class="title">Outcomes</h5> <p>We attempted to extract both timeâtoâevent data (for survival outcome) and categorical data (for all outcomes). However, none of the studies reported timeâtoâevent data for participants with cancer. </p> <p>For dichotomous data, we extracted data necessary to conduct a complete case analysis as the primary analysis. We collected allâcause mortality at three months. For studies where VTE was not reported as a separate outcome, we added the number of events of DVT and PE. </p> <p>We attempted to contact study authors for incompletely reported data. We decided a priori to consider abstracts in the main analysis only if study authors supplied us with full reports of their methods and results; otherwise, abstracts were included only in the sensitivity analysis. </p> </section> <section id="CD006649-sec-0032"> <h5 class="title">Other</h5> <p>We extracted from each included trial any information on the following points.</p> <p> <ul id="CD006649-list-0006"> <li> <p>Source of funding.</p> </li> <li> <p>Ethical approval.</p> </li> <li> <p>Conflicts of interest.</p> </li> </ul> </p> </section> </section> <section id="CD006649-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias at the study level using Cochrane's risk of bias tool (<a href="./references#CD006649-bbs2-0119" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). The review authors independently assessed the methodologic quality of each included study and resolved any disagreements through discussion. Risk of bias criteria included the following. </p> <p> <ul id="CD006649-list-0007"> <li> <p>Adequate sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias (e.g. whether the study was stopped early for benefit).</p> </li> </ul> </p> <p>See section on <a href="#CD006649-sec-0036">Dealing with missing data</a> about assessing risk of bias associated with participants with missing data per outcome and across studies. </p> </section> <section id="CD006649-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed risk ratios (RRs) for dichotomous data. None of the outcomes of interest were metaâanalysed as a continuous variable. </p> </section> <section id="CD006649-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant.</p> </section> <section id="CD006649-sec-0036"> <h4 class="title">Dealing with missing data</h4> <section id="CD006649-sec-0037"> <h5 class="title">Determining participants with missing data</h5> <p>It was unclear whether certain participant categories (e.g. those described as 'withdrew consent' or 'experienced adverse events') were actually followed up by the trial authors (versus had missing participant data) (<a href="./references#CD006649-bbs2-0104" title="AklEA , KahaleLA , EbrahimS , Alonso-CoelloP , SchÃ¼nemannHJ , GuyattGH . Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers. Journal of Clinical Epidemiology2016;76:147-54.">Akl 2016</a>). To identify participants with missing data, we followed the guidance suggested by Kahale and colleagues (<a href="./references#CD006649-bbs2-0123" title="KahaleLA , GuyattGH , AgoritsasT , BrielM , BusseJW , Carrasco-LabraA , et al. A guidance was developed to identify participants with missing outcome data in randomized controlled trials. Journal of Clinical Epidemiology2019;115:55-63.">Kahale 2019</a>): </p> <p> <ul id="CD006649-list-0008"> <li> <p>Definitely not missing data: (1) participants explicitly reported as followed up; (2) participants who died during the trial; (3) participants belonging to centres that were excluded. </p> </li> <li> <p>Definitely missing data: (1) participants explicitly reported as not followed up; (2) participants with unclear followâup status and (a) excluded from the denominator of the analysis (i.e. complete case analysis); or (b) included in the denominator of the analysis and their outcomes were explicitly stated to be imputed. However, the systematic reviewers should not treat them as missing data unless it is possible to obtain the number of observed/actual events (i.e. excluding imputed events) to avoid double counting. </p> </li> <li> <p>Potentially missing data: participants with unclear followâup status (e.g. included in the denominator of the analysis and their outcomes were not explicitly stated to be imputed). </p> </li> </ul> </p> </section> <section id="CD006649-sec-0038"> <h5 class="title">Dealing with participants with missing data in the primary metaâanalysis</h5> <p>In the primary metaâanalysis, we used a complete case analysis approach (i.e. we excluded participants considered to have missing data) (<a href="./references#CD006649-bbs2-0114" title="GuyattGH , EbrahimS , Alonso-CoelloP , JohnstonBC , MathioudakisAG , BrielM , et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology2017;87:14-22.">Guyatt 2017</a>). </p> <p>For categorical data, we used the following calculations for each study arm.</p> <p> <ul id="CD006649-list-0009"> <li> <p>Denominator: (number of participants randomised) â (number of participants with definitely missing data). </p> </li> <li> <p>Numerator: number of participants with observed events (i.e. participants who experienced at least one event for the outcome of interest during their available followâup time). </p> </li> </ul> </p> <p>For continuous data, we planned to use for each study arm the reported mean and standard deviation (SD) for participants actually followed up by the trial authors. </p> </section> <section id="CD006649-sec-0039"> <h5 class="title">Assessing the risk of bias associated with participants with missing data</h5> <p>When the primary metaâanalysis of a specific outcome found a statistically significant effect, we conducted sensitivity metaâanalyses to assess the risk of bias associated with missing participant data. Those sensitivity metaâanalyses used a priori plausible assumptions about the outcomes of participants considered to have missing data. The assumptions we used in the sensitivity metaâanalyses were increasingly stringent to progressively challenge the statistical significance of the results of the primary analysis (<a href="./references#CD006649-bbs2-0103" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PloS One2013;8(2):e57132.">Akl 2013</a>;Â <a href="./references#CD006649-bbs2-0111" title="EbrahimS , AklEA , MustafaRA , SunX , WalterSD , Heels-AnsdellD , et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology2013;66(9):1014-21.">Ebrahim 2013</a>). </p> <p>For categorical data, and for RR showing a reduction in effect (RR &lt; 1), we used the following increasingly stringent but plausible assumptions (<a href="./references#CD006649-bbs2-0103" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PloS One2013;8(2):e57132.">Akl 2013</a>). </p> <p> <ul id="CD006649-list-0010"> <li> <p>For the control arm, relative incidence (RI) among those with missing data or lost to followâup (LTFU) compared to those with available data (followed up, FU) in the same arm (RI<sub>LTFU/FU</sub>) = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 1.5; </p> </li> <li> <p>for the control arm, RI<sub>LTFU/FU</sub> = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 2; </p> </li> <li> <p>for the control arm, RI<sub>LTFU/FU</sub> = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 3; </p> </li> <li> <p>for the control arm, RI<sub>LTFU/FU</sub> = 1; for the intervention arm, RI<sub>LTFU/FU</sub> = 5. </p> </li> </ul> </p> <p>For RR showing an increase in effect (RR &gt; 1), we switched the above assumptions between the control and interventions arms (i.e. used RI<sub>LTFU/FU</sub> = 1 for the intervention arm). </p> <p>Specifically, we used the following calculations for each study arm.</p> <p> <ul id="CD006649-list-0011"> <li> <p>Denominator: (number of participants randomised) â (number of participants with definitely missing data). </p> </li> <li> <p>Numerator: (number of participants with observed events) + (number of participants with definitely missing data, with assumed events). </p> </li> </ul> </p> <p>Assumed events were calculated by applying the a priori plausible assumptions to the participants considered definitely with missing data. </p> <p>For continuous data, we planned to use the four strategies suggested by Ebrahim and colleagues (<a href="./references#CD006649-bbs2-0111" title="EbrahimS , AklEA , MustafaRA , SunX , WalterSD , Heels-AnsdellD , et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology2013;66(9):1014-21.">Ebrahim 2013</a>). The strategies impute the means for participants with missing data based on the means of participants actually followed up in individual trials included in the systematic review. To impute SD, we used the median SD from the control arms of all included trials (<a href="./references#CD006649-bbs2-0111" title="EbrahimS , AklEA , MustafaRA , SunX , WalterSD , Heels-AnsdellD , et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology2013;66(9):1014-21.">Ebrahim 2013</a>). </p> </section> </section> <section id="CD006649-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity between trials by visual inspection of forest plots, estimation of the percentage heterogeneity between trials that could not be ascribed to sampling variation (I<sup>2</sup> test; <a href="./references#CD006649-bbs2-0118" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327:557-60.">Higgins 2003</a>), and by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD006649-bbs2-0108" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , Davey SmithG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. London (UK): BMJ Publication Group, 2001.">Deeks 2001</a>).Â If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons for this (see <a href="#CD006649-sec-0043">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> <section id="CD006649-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We explored whether the study was included in a trial registry and whether a protocol was available. We planned to create funnel plots for outcomes including 10 or more trials. </p> </section> <section id="CD006649-sec-0042"> <h4 class="title">Data synthesis</h4> <p>For dichotomous data, we calculated the RR separately for each study (<a href="./references#CD006649-bbs2-0109" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">DerSimonian 1986</a>;Â <a href="./references#CD006649-bbs2-0134" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). As noted earlier, in the primary metaâanalysis, we used a complete case analysis approach; that is, we excluded participants considered to have missing data (<a href="./references#CD006649-bbs2-0114" title="GuyattGH , EbrahimS , Alonso-CoelloP , JohnstonBC , MathioudakisAG , BrielM , et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology2017;87:14-22.">Guyatt 2017</a>). When analysing data related to participants who were reported as not compliant, we attempted to adhere to the principles of intentionâtoâtreat (ITT) analysis. We approached the issue of nonâcompliance independently from that of missing data (<a href="./references#CD006649-bbs2-0105" title="AlshurafaM , BrielM , AklEA , HainesT , MoayyediP , GentlesSJ , et al. Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PloS One2012;7(11):e49163.">Alshurafa 2012</a>). We then pooled the results of the different studies using a randomâeffects model. </p> </section> <section id="CD006649-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses based on characteristics of participants, but did not conduct them as the data were not available. </p> </section> <section id="CD006649-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We decided a priori to include abstracts in the sensitivity analysis if study authors did not provide us with full reports of their methods and results. As described earlier, we also planned for sensitivity metaâanalyses to assess the risk of bias associated with missing participant data when the primary metaâanalysis of a specific outcome found a statistically significant effect. </p> </section> <section id="CD006649-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the certainty of evidence at the outcome level using the GRADE approach (<a href="./references#CD006649-bbs2-0138" title="SchÃ¼nemannH , BroÅ¼ekJ , GuyattG , Oxman A (editors). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">SchÃ¼nemann 2013</a>). We followed the guidance developed by the GRADE working group to communicate the findings of the systematic review (<a href="./references#CD006649-bbs2-0137" title="SantessoN , GlentonC , DahmP , GarnerP , AklEA , AlperB , et al. GRADE guidelines 26: informative statements to communicatethe findings of systematic reviews of interventions. Journal ofClinical Epidemiology2020;119:126-35.">Santesso 2020</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006649-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006649-sec-0046"></div> <section id="CD006649-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD006649-sec-0048"> <h4 class="title">Results of the search</h4> <p>The 14 August 2021 search strategy identified 3073 unique citations.Â <a href="#CD006649-fig-0001">Figure 1</a>Â shows the study flow. Our search identified no new eligible studies. The title and abstract screening identified 147citations as potentially eligible for this review. We included 13 eligible RCTs published as full reports (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>;Â <a href="./references#CD006649-bbs2-0002" title="BÃ¼llerHR , GentM , GallusAS , GinsbergJ , PrinsMH , BaildonR , et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657-62. ">BÃ¼ller 1997 (COLOMBUS)</a>;Â <a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>;Â <a href="./references#CD006649-bbs2-0004" title="HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine1992;326(15):975-82. ">Hull 1992</a>;Â <a href="./references#CD006649-bbs2-0005" title="KoopmanMM , PrandoniP , PiovellaF , OckelfordPA , BrandjesDP , Van der MeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine1996;334(11):682-7. ">Koopman 1996</a>;Â <a href="./references#CD006649-bbs2-0006" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine1996;334(11):677-81. ">Levine 1996</a>;Â <a href="./references#CD006649-bbs2-0009" title="MerliG , SpiroTE . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191-202. ">Merli 2001</a>;Â <a href="./references#CD006649-bbs2-0010" title="PrandoniP , LensingAW , BÃ¼llerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet1992;339(8791):441-5. ">Prandoni 1992</a>;Â <a href="./references#CD006649-bbs2-0011" title="PrandoniP , CarnovaliM , MarchioriA , Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164(10):1077. ">Prandoni 2004 (GALILEI)</a>;Â <a href="./references#CD006649-bbs2-0012" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Archives of Internal Medicine1993;153(13):1541-6. ">Simonneau 1993</a>;Â <a href="./references#CD006649-bbs2-0013" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJP , AzarianR , et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire. New England Journal of Medicine1997;337(10):663-9. ">Simonneau 1997 (THESEE)</a>;Â <a href="./references#CD006649-bbs2-0014" title="BÃ¼llerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140:867-73. Van DoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusAG , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101:762-9. ">Van Doormaal 2009</a>;Â <a href="./references#CD006649-bbs2-0015" title="WellsPS , AndersonDR , RodgerMA , ForgieMA , FlorackP , TouchieD , et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine2005;165:733-8. ">Wells 2005</a>), and two studies published as abstracts (<a href="./references#CD006649-bbs2-0007" title="LindmarkerP , HolstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):186-90. ">Lindmarker 1994</a>;Â <a href="./references#CD006649-bbs2-0008" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14-8. ">Lopaciuk 1992</a>). Agreement between review authors for study eligibility was excellent (kappa = 0.94). </p> <div class="figure" id="CD006649-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD006649-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD006649-sec-0049"> <h4 class="title">Included studies</h4> <p>In all 15 included studies, participants with cancer constituted subgroups. Of these 15 studies, three studies reported data for cancer subgroups (<a href="./references#CD006649-bbs2-0010" title="PrandoniP , LensingAW , BÃ¼llerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet1992;339(8791):441-5. ">Prandoni 1992</a>;Â <a href="./references#CD006649-bbs2-0012" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Archives of Internal Medicine1993;153(13):1541-6. ">Simonneau 1993</a>;Â <a href="./references#CD006649-bbs2-0014" title="BÃ¼llerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140:867-73. Van DoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusAG , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101:762-9. ">Van Doormaal 2009</a>), and three studies had followâup publications reporting cancer subgroup data (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>;Â <a href="./references#CD006649-bbs2-0004" title="HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine1992;326(15):975-82. ">Hull 1992</a>;Â <a href="./references#CD006649-bbs2-0009" title="MerliG , SpiroTE . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191-202. ">Merli 2001</a>). For two studies, we obtained cancer subgroup data from the study authors (<a href="./references#CD006649-bbs2-0011" title="PrandoniP , CarnovaliM , MarchioriA , Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164(10):1077. ">Prandoni 2004 (GALILEI)</a>;Â <a href="./references#CD006649-bbs2-0015" title="WellsPS , AndersonDR , RodgerMA , ForgieMA , FlorackP , TouchieD , et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine2005;165:733-8. ">Wells 2005</a>). Seven studies did not report cancer subgroup data (<a href="./references#CD006649-bbs2-0002" title="BÃ¼llerHR , GentM , GallusAS , GinsbergJ , PrinsMH , BaildonR , et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657-62. ">BÃ¼ller 1997 (COLOMBUS)</a>;Â <a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>;Â <a href="./references#CD006649-bbs2-0005" title="KoopmanMM , PrandoniP , PiovellaF , OckelfordPA , BrandjesDP , Van der MeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine1996;334(11):682-7. ">Koopman 1996</a>;Â <a href="./references#CD006649-bbs2-0006" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine1996;334(11):677-81. ">Levine 1996</a>;Â <a href="./references#CD006649-bbs2-0007" title="LindmarkerP , HolstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):186-90. ">Lindmarker 1994</a>;Â <a href="./references#CD006649-bbs2-0008" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14-8. ">Lopaciuk 1992</a>;Â <a href="./references#CD006649-bbs2-0013" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJP , AzarianR , et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire. New England Journal of Medicine1997;337(10):663-9. ">Simonneau 1997 (THESEE)</a>), so we used the data as reported in two published systematic reviews (<a href="./references#CD006649-bbs2-0117" title="HettiarachchiRJ , SmorenburgSM , GinsbergJ , LevineM , PrinsMH , BullerHR . Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thrombosis and Haemostasis1999;82:947-52.">Hettiarachchi 1999</a>;Â <a href="./references#CD006649-bbs2-0135" title="RobertsonL , JonesLE . Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD001100. [DOI: 10.1002/14651858.CD001100.pub4]">Robertson 2017</a>). We excluded these seven studies from the main analysis and included them in the sensitivity analyses. </p> <p>Of the 15 studies, 13 compared LMWH to UFH, one compared fondaparinux to heparin (UFH and LMWH) (<a href="./references#CD006649-bbs2-0014" title="BÃ¼llerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140:867-73. Van DoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusAG , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101:762-9. ">Van Doormaal 2009</a>), and one compared dalteparin to tinzaparin (<a href="./references#CD006649-bbs2-0015" title="WellsPS , AndersonDR , RodgerMA , ForgieMA , FlorackP , TouchieD , et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine2005;165:733-8. ">Wells 2005</a>). None of the studies specified the types of cancer of the participants. In 14 of 15 studies, the initial parenteral anticoagulation was followed by oral anticoagulation for at least three months. InÂ <a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>, the longâterm anticoagulation was either subcutaneous (SC) UFH or oral anticoagulation, depending on the usual regimen of the participating centre (<a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>). </p> <p>Breddin and colleagues recruited 83 people with cancer, aged at least 18 years, with DVT (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>). Overall, the study enrolled 1137 participants. Participants were randomised to receive intravenous (IV) UFH for five to seven days or SC reviparin twice a day for five to seven days or once a day for a mean (SD) of 28 Â± 2 days. All the participants received a vitamin K antagonist (VKA) until the end of the 90âday observation period. The primary efficacy outcome was a change in the venographically determined thrombus size. Assessed outcomes were recurrence of DVT or PE. Participants were followed up for 90 days. The authors reported 91% followâup. </p> <p>Buller and colleagues recruited 232 people with cancer, aged at least 18 years, with proximal or distal DVT, PE, or both (<a href="./references#CD006649-bbs2-0002" title="BÃ¼llerHR , GentM , GallusAS , GinsbergJ , PrinsMH , BaildonR , et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657-62. ">BÃ¼ller 1997 (COLOMBUS)</a>). Participants were randomised to receive weightâbased SC reviparin twice daily at home or IV UFH (target activated partial thromboplastin time (aPTT) 1.5 to 2.5) in hospital for five days. Oral anticoagulant treatment with a derivative of coumarin was begun concomitantly on the first or second day and continued for 12 weeks. Assessed outcomes were symptomatic recurrent VTE, major bleeding, and death. Participants were followed up for 12 weeks. The study authors reported complete followâup. </p> <p>Duroux and colleagues recruited 18 people with cancer, aged at least 18 years, with proximal DVT but no PE (<a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>). Overall, the study enrolled 170 participants. Participants were randomised to receive nadroparin twice daily for 10 days, or IV UFH (target aPTT 1.5 to 2) for 10 days. After day 10, each centre continued its usual anticoagulant regimen either by SC UFH at adjusted dose or by oral anticoagulant for 12 weeks. Assessed outcomes were mortality, recurrent venogramâdetected VTE, and major bleeding. The study authors did not report information about followâup in the cancer subgroup. </p> <p>Hull and colleagues recruited 95 people with cancer, aged at least 18 years, with proximal DVT (<a href="./references#CD006649-bbs2-0004" title="HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine1992;326(15):975-82. ">Hull 1992</a>). Overall, the study enrolled 432 participants. Participants were randomised to receive SC tinzaparin once daily or IV UFH (target aPTT 1.5 to 2.5) for six days. All participants received longâterm therapy with warfarin for at least three months. Participants assigned to receive IV UFH also received a SC injection of placebo once every 24 hours. Participants assigned to receive SC LMWH also received an IV bolus of placebo and a continuous IV infusion of placebo throughout the initial therapy. Assessed outcomes were recurrent VTE, bleeding complications, and participant death. Participants were followed up for three months. The authors reported complete followâup. </p> <p>Koopman and colleagues recruited 70 people with cancer, aged at least 18 years and with a life expectancy of minimum six months, with proximal DVT (<a href="./references#CD006649-bbs2-0005" title="KoopmanMM , PrandoniP , PiovellaF , OckelfordPA , BrandjesDP , Van der MeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine1996;334(11):682-7. ">Koopman 1996</a>). Overall, the study enrolled 400 participants. Participants were randomised to receive SC nadroparin twice daily at home or IV UFH (target aPTT 1.5 to 2) for five days. In each participant, VKA therapy was begun on the first day after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the international normalised ratio (INR) between 2.0 and 3.0. The primary outcome studied was symptomatic recurrent VTE, while the secondary outcome was major bleeding. All participants were contacted daily during the initial treatment and at 4, 12, and 24 weeks. The authors reported complete followâup. </p> <p>Levine and colleagues recruited 103 people with cancer with proximal or distal DVT (<a href="./references#CD006649-bbs2-0006" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine1996;334(11):677-81. ">Levine 1996</a>). Overall, the study enrolled 500 participants. Participants were randomised to receive treatment with either SC enoxaparin at home or continuous IV UFH in the hospital for five days. In all participants, warfarin therapy was begun on the second day after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes were symptomatic recurrent VTE and bleeding during the period of administration of study medication or within 48 hours after its discontinuation. The participants were assessed monthly for three months. The authors reported complete followâup. </p> <p>Lindmarker and colleagues recruited 16 people with cancer, aged at least 18 years, with DVT (<a href="./references#CD006649-bbs2-0007" title="LindmarkerP , HolstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):186-90. ">Lindmarker 1994</a>). Overall, the study enrolled 204 participants. Participants were randomised to receive SC Fragmin once daily compared to IV UFH (target aPTT 1.5 to 3.0) for five days. In all participants, warfarin therapy was given for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes were mortality, recurrent VTE, and bleeding. Participants were followed up for six months. The authors reported complete followâup. </p> <p>Lopaciuk and colleagues recruited nine people with cancer with proximal or distal DVT, or both, of the leg (<a href="./references#CD006649-bbs2-0008" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14-8. ">Lopaciuk 1992</a>). Overall, the study enrolled 149 participants. Participants were randomised to receive either fixed dose nadroparin (LMWH) or UFH (doses adjusted according to aPTT) for 10 days. In all participants, VKA therapy was begun on the seventh day after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes were size of the thrombus preâ and postâtreatment and recurrent VTE. Participants were followed up for three months. The authors reported complete followâup. </p> <p>Merli and colleagues recruited 141 people with cancer, aged at least 18 years, with DVT or PE (<a href="./references#CD006649-bbs2-0009" title="MerliG , SpiroTE . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191-202. ">Merli 2001</a>). Overall, the study enrolled 204 participants. Participants were randomised to receive SC enoxaparin (1 mg/kg twice daily or 1.5 mg/kg once daily) or IV UFH (target aPTT 55 to 80 seconds) for five days. In all participants, warfarin was started within 72 hours of initial study drug administration to keep INR between 2.0 and 3.0. Assessed outcomes included recurrent DVT or PE. Participants were followed up for three months.Â  No information about followâup in the cancer subgroup was reported. </p> <p>Prandoni and colleagues recruited 33 people with cancer, aged at least 18 years, with proximal DVT (<a href="./references#CD006649-bbs2-0010" title="PrandoniP , LensingAW , BÃ¼llerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet1992;339(8791):441-5. ">Prandoni 1992</a>). Overall, the study enrolled 170 participants. Participants were randomised to receive weightâbased SC nadroparin twice daily or IV UFH (target aPTT 1.5 to 2.0) for 10 days. In all participants, coumarin was begun on the seventh day after commencing initial therapy and continued for at least three months. The dose of coumarin was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes included symptomatic recurrent DVT or PE. Participants were followed up for six months. The authors reported complete followâup. </p> <p>Prandoni and colleagues recruited 156 people with cancer, aged at least 18 years and with a life expectancy of minimum three months, with DVT, PE, or both (<a href="./references#CD006649-bbs2-0011" title="PrandoniP , CarnovaliM , MarchioriA , Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164(10):1077. ">Prandoni 2004 (GALILEI)</a>). Overall, the study enrolled 720 participants. Participants were randomised to receive nadroparin twice daily or SC UFH twice daily (target aPTT 50 to 90 seconds) for five days. In all participants, VKA therapy was begun on the first or second day after commencing initial therapy and continued for 12 weeks. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. The primary endpoint was the incidence of symptomatic recurrent VTE during the threeâmonth study period. A secondary outcome was the incidence of major bleeding during the initial LMWH treatment and additional 48 hours. During the initial treatment with the study drugs, participants were examined daily. Followâup visits were scheduled after one and three months. The authors reported complete followâup. </p> <p>Simonneau recruited nine people with cancer, aged at least 18 years, with proximal DVT (<a href="./references#CD006649-bbs2-0012" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Archives of Internal Medicine1993;153(13):1541-6. ">Simonneau 1993</a>). Overall, the study enrolled 134 participants. Participants were randomised to receive SC enoxaparin twice daily or IV UFH for 10 days (target aPTT 1.5 to 2.5). In all participants, VKA therapy was begun on the tenth day after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Outcomes assessed were mortality, recurrent symptomatic VTE, and bleeding. Participants were followed up for three months. The authors reported complete followâup. </p> <p>Simonneau and colleagues recruited 60 people with cancer, aged at least 18 years and with a life expectancy of minimum three months, with clinically suspected PE (<a href="./references#CD006649-bbs2-0013" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJP , AzarianR , et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire. New England Journal of Medicine1997;337(10):663-9. ">Simonneau 1997 (THESEE)</a>). Overall, the study enrolled 612 participants. Participants were randomised to receive SC tinzaparin once daily or IV UFH (target aPTT 2 to 3) for five days. In all participants, VKA therapy was begun on the first three days after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Outcomes assessed were mortality, recurrent symptomatic VTE, and major bleeding. Participants were followed up for 90 days. The authors reported complete followâup. </p> <p>Van Doormaal and colleagues recruited 477 people with cancer, aged at least 18 years, with acute symptomatic DVT without PE (subgroup analysis of MATISSE study) (<a href="./references#CD006649-bbs2-0014" title="BÃ¼llerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140:867-73. Van DoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusAG , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101:762-9. ">Van Doormaal 2009</a>). Participants were randomised to receive SC fondaparinux once daily, or enoxaparin twice daily, or UFH (target aPTT 1.5 to 2.5). In all participants, VKA therapy was begun as soon as possible but not later than 72 hours after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes were mortality, symptomatic recurrent VTE, and bleeding. Participants were followed up for 90 days. The authors reported complete followâup. </p> <p>Wells and colleagues recruited 113 people with cancer, aged at least 18 years, with upper or lower extremity DVT (<a href="./references#CD006649-bbs2-0015" title="WellsPS , AndersonDR , RodgerMA , ForgieMA , FlorackP , TouchieD , et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine2005;165:733-8. ">Wells 2005</a>). Overall, the study enrolled 505 participants. Participants were randomised to receive SC tinzaparin once daily or SC dalteparin once daily on an outpatient basis. In all participants, warfarin therapy was begun within 24 hours of the first dose of LMWH and continued for three months. Assessed outcomes were mortality, symptomatic recurrent VTE, and major and minor bleeding. Participants were followed up for three months. The authors reported complete followâup. </p> </section> <section id="CD006649-sec-0050"> <h4 class="title">Excluded studies</h4> <p>Of the 131 excluded fullâtext articles, in 11 fullâtext articles, people with cancer constituted study subgroups but their outcome data were not available (<a href="./references#CD006649-bbs2-0019" title="AlbadaJ , NieuwenhuisHK , SixmaJJ . Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation1989;80(4):935-40. ">Albada 1989</a>;Â <a href="./references#CD006649-bbs2-0025" title="BelcaroG , NicolaidesAN , CesaroneMR , LauroraG , De SanctisMT , IncandelaL . Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology1999;50(10):781-7. ">Belcaro 1999</a>;Â <a href="./references#CD006649-bbs2-0029" title="BrattG , AbergW , JohanssonM , TornebohmE , GranqvistS , LocknerD . Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thrombosis and Haemostasis1990;64(4):506-10. ">Bratt 1990</a>;Â <a href="./references#CD006649-bbs2-0031" title="BÃ¼llerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867-73. ">BÃ¼ller 2004</a>;Â <a href="./references#CD006649-bbs2-0044" title="FiessingerJN , Lopez-FernandezM , GattererE , GranqvistS , KherA , OlssonCG , et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis and Haemostasis1996;76(2):195-9. ">Fiessinger 1996</a>;Â <a href="./references#CD006649-bbs2-0051" title="HarenbergJ , HuckK , BratschH , StehleG , DempfleCE , MallK , et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis1990;20 Suppl 1:205-19. ">Harenberg 1990</a>;Â <a href="./references#CD006649-bbs2-0053" title="HarenbergJ , SchmidtJA , KoppenhagenK , TolleA , HuismanMV , BullerHR . Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis and Haemostasis2000;83(5):652-6. ">Harenberg 2000</a>;Â <a href="./references#CD006649-bbs2-0056" title="HolmHA , LyB , HandelandGF , AbildgaardU , ArnesenKE , GottschalkP , et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis1986;16 Suppl 2:30-7. ">Holm 1986</a>;Â <a href="./references#CD006649-bbs2-0058" title="HullRD , RaskobGE , BrantRF , PineoGF , ElliottG , SteinPD , et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Archives of Internal Medicine2000;160(2):229-36. ">Hull 2000</a>;Â <a href="./references#CD006649-bbs2-0069" title="LoumanmakiK , GrankvistS , HallertC , JauroI , KetolaK , KimHC . A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. Journal of Internal Medicine1996;240(2):85-92. ">Luomanmaki 1996</a>;Â <a href="./references#CD006649-bbs2-0086" title="RiessH , KoppenhagenK , TolleA , Kemkes-MatthesB , GraveM , PatekF , et al. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thrombosis and Haemostasis2003;90(2):252-9. ">Riess 2003</a>). We excluded the remaining 123 articles for the following reasons: not population of interest (86 studies); not intervention of interest (17 studies); no relevant data for cancer subgroup (n= 1); and not design of interest (27 studies). </p> </section> </section> <section id="CD006649-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>The judgments for the risk of bias are summarised in <a href="#CD006649-fig-0002">Figure 2</a> and <a href="#CD006649-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006649-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study" data-id="CD006649-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD006649-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies" data-id="CD006649-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD006649-sec-0052"> <h4 class="title">Allocation</h4> <p>We judged allocation to be adequately concealed in 13 of the 15 studies (<a href="./references#CD006649-bbs2-0002" title="BÃ¼llerHR , GentM , GallusAS , GinsbergJ , PrinsMH , BaildonR , et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657-62. ">BÃ¼ller 1997 (COLOMBUS)</a>; <a href="./references#CD006649-bbs2-0004" title="HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine1992;326(15):975-82. ">Hull 1992</a>; <a href="./references#CD006649-bbs2-0005" title="KoopmanMM , PrandoniP , PiovellaF , OckelfordPA , BrandjesDP , Van der MeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine1996;334(11):682-7. ">Koopman 1996</a>; <a href="./references#CD006649-bbs2-0006" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine1996;334(11):677-81. ">Levine 1996</a>; <a href="./references#CD006649-bbs2-0007" title="LindmarkerP , HolstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):186-90. ">Lindmarker 1994</a>; <a href="./references#CD006649-bbs2-0008" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14-8. ">Lopaciuk 1992</a>; <a href="./references#CD006649-bbs2-0009" title="MerliG , SpiroTE . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191-202. ">Merli 2001</a>; <a href="./references#CD006649-bbs2-0010" title="PrandoniP , LensingAW , BÃ¼llerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet1992;339(8791):441-5. ">Prandoni 1992</a>; <a href="./references#CD006649-bbs2-0011" title="PrandoniP , CarnovaliM , MarchioriA , Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164(10):1077. ">Prandoni 2004 (GALILEI)</a>; <a href="./references#CD006649-bbs2-0012" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Archives of Internal Medicine1993;153(13):1541-6. ">Simonneau 1993</a>; <a href="./references#CD006649-bbs2-0013" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJP , AzarianR , et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire. New England Journal of Medicine1997;337(10):663-9. ">Simonneau 1997 (THESEE)</a>; <a href="./references#CD006649-bbs2-0014" title="BÃ¼llerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140:867-73. Van DoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusAG , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101:762-9. ">Van Doormaal 2009</a>; <a href="./references#CD006649-bbs2-0015" title="WellsPS , AndersonDR , RodgerMA , ForgieMA , FlorackP , TouchieD , et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine2005;165:733-8. ">Wells 2005</a>). Two studies did not report on allocation concealment (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>; <a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>). </p> </section> <section id="CD006649-sec-0053"> <h4 class="title">Blinding</h4> <section id="CD006649-sec-0054"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>We judged participants and personnel to be definitely blinded in three of the 15 studies (<a href="./references#CD006649-bbs2-0004" title="HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine1992;326(15):975-82. ">Hull 1992</a>; <a href="./references#CD006649-bbs2-0014" title="BÃ¼llerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140:867-73. Van DoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusAG , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101:762-9. ">Van Doormaal 2009</a>; <a href="./references#CD006649-bbs2-0015" title="WellsPS , AndersonDR , RodgerMA , ForgieMA , FlorackP , TouchieD , et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine2005;165:733-8. ">Wells 2005</a>), and definitely not blinded in 12 studies (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>; <a href="./references#CD006649-bbs2-0002" title="BÃ¼llerHR , GentM , GallusAS , GinsbergJ , PrinsMH , BaildonR , et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657-62. ">BÃ¼ller 1997 (COLOMBUS)</a>; <a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>; <a href="./references#CD006649-bbs2-0005" title="KoopmanMM , PrandoniP , PiovellaF , OckelfordPA , BrandjesDP , Van der MeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine1996;334(11):682-7. ">Koopman 1996</a>; <a href="./references#CD006649-bbs2-0006" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine1996;334(11):677-81. ">Levine 1996</a>; <a href="./references#CD006649-bbs2-0007" title="LindmarkerP , HolstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):186-90. ">Lindmarker 1994</a>; <a href="./references#CD006649-bbs2-0008" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14-8. ">Lopaciuk 1992</a>; <a href="./references#CD006649-bbs2-0009" title="MerliG , SpiroTE . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191-202. ">Merli 2001</a>; <a href="./references#CD006649-bbs2-0010" title="PrandoniP , LensingAW , BÃ¼llerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet1992;339(8791):441-5. ">Prandoni 1992</a>; <a href="./references#CD006649-bbs2-0011" title="PrandoniP , CarnovaliM , MarchioriA , Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164(10):1077. ">Prandoni 2004 (GALILEI)</a>; <a href="./references#CD006649-bbs2-0012" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Archives of Internal Medicine1993;153(13):1541-6. ">Simonneau 1993</a>; <a href="./references#CD006649-bbs2-0013" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJP , AzarianR , et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire. New England Journal of Medicine1997;337(10):663-9. ">Simonneau 1997 (THESEE)</a>). </p> </section> <section id="CD006649-sec-0055"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>We judged outcome assessors to be definitely blinded in 14 studies (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>; <a href="./references#CD006649-bbs2-0002" title="BÃ¼llerHR , GentM , GallusAS , GinsbergJ , PrinsMH , BaildonR , et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657-62. ">BÃ¼ller 1997 (COLOMBUS)</a>; <a href="./references#CD006649-bbs2-0004" title="HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine1992;326(15):975-82. ">Hull 1992</a>; <a href="./references#CD006649-bbs2-0005" title="KoopmanMM , PrandoniP , PiovellaF , OckelfordPA , BrandjesDP , Van der MeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine1996;334(11):682-7. ">Koopman 1996</a>; <a href="./references#CD006649-bbs2-0006" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine1996;334(11):677-81. ">Levine 1996</a>; <a href="./references#CD006649-bbs2-0007" title="LindmarkerP , HolstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):186-90. ">Lindmarker 1994</a>; <a href="./references#CD006649-bbs2-0008" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14-8. ">Lopaciuk 1992</a>; <a href="./references#CD006649-bbs2-0009" title="MerliG , SpiroTE . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191-202. ">Merli 2001</a>; <a href="./references#CD006649-bbs2-0010" title="PrandoniP , LensingAW , BÃ¼llerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet1992;339(8791):441-5. ">Prandoni 1992</a>; <a href="./references#CD006649-bbs2-0011" title="PrandoniP , CarnovaliM , MarchioriA , Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164(10):1077. ">Prandoni 2004 (GALILEI)</a>; <a href="./references#CD006649-bbs2-0012" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Archives of Internal Medicine1993;153(13):1541-6. ">Simonneau 1993</a>; <a href="./references#CD006649-bbs2-0013" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJP , AzarianR , et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire. New England Journal of Medicine1997;337(10):663-9. ">Simonneau 1997 (THESEE)</a>; <a href="./references#CD006649-bbs2-0014" title="BÃ¼llerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140:867-73. Van DoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusAG , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101:762-9. ">Van Doormaal 2009</a>; <a href="./references#CD006649-bbs2-0015" title="WellsPS , AndersonDR , RodgerMA , ForgieMA , FlorackP , TouchieD , et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine2005;165:733-8. ">Wells 2005</a>), and probably not blinded in one study (<a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>). </p> </section> </section> <section id="CD006649-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>All but three studies reported complete followâup (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>; <a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>; <a href="./references#CD006649-bbs2-0009" title="MerliG , SpiroTE . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191-202. ">Merli 2001</a>). Breddin and colleagues reported an approximate 91% followâup in the cancer subgroup (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>). For the other two studies, no information about followâup in the cancer subgroup was reported (<a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>; <a href="./references#CD006649-bbs2-0009" title="MerliG , SpiroTE . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191-202. ">Merli 2001</a>); hence, we analysed the available data assuming that any possibly missing data were missing at random. </p> </section> <section id="CD006649-sec-0057"> <h4 class="title">Selective reporting</h4> <p>The outcomes listed in the methods section were reported in the results section for all 15 studies. We did not suspect selective reporting of outcomes for any of the studies. The cancer subgroup data were missing for seven studies. </p> </section> <section id="CD006649-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>None suspected.</p> </section> </section> <section id="CD006649-sec-0059"> <h3 class="title" id="CD006649-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD006649-tbl-0001"><b>Summary of findings 1</b> Low molecular weight heparin compared to unfractionated heparin</a>; <a href="./full#CD006649-tbl-0002"><b>Summary of findings 2</b> Fondaparinux compared to heparin</a>; <a href="./full#CD006649-tbl-0003"><b>Summary of findings 3</b> Dalteparin compared to tinzaparin</a> </p> <section id="CD006649-sec-0060"> <h4 class="title">Low molecular weight heparin versus unfractionated heparin</h4> <section id="CD006649-sec-0061"> <h5 class="title">Mortality</h5> <p>Metaâanalysis of the five RCTs, including 418 participants, found that LMWH compared to UFH may reduce mortality at three months (RR 0.66, 95% CI 0.40 to 1.10; risk difference (RD) 57 fewer per 1000, 95% CI 101 fewer to 17 more; low certainty evidence; <a href="./references#CD006649-fig-0004" title="">Analysis 1.1</a>) (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>; <a href="./references#CD006649-bbs2-0004" title="HullRD , RaskobGE , PineoGF , GreenD , TrowbridgeAA , ElliottCG , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. New England Journal of Medicine1992;326(15):975-82. ">Hull 1992</a>; <a href="./references#CD006649-bbs2-0010" title="PrandoniP , LensingAW , BÃ¼llerHR , CartaM , CogoA , VigoM , et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet1992;339(8791):441-5. ">Prandoni 1992</a>; <a href="./references#CD006649-bbs2-0011" title="PrandoniP , CarnovaliM , MarchioriA , Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164(10):1077. ">Prandoni 2004 (GALILEI)</a>; <a href="./references#CD006649-bbs2-0012" title="SimonneauG , CharbonnierB , DecoususH , PlanchonB , NinetJ , SieP , et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Archives of Internal Medicine1993;153(13):1541-6. ">Simonneau 1993</a>). The I<sup>2</sup> value showed no heterogeneity (I<sup>2</sup> = 0%). We judged the certainty of evidence to be low due to very serious imprecision (see <a href="./full#CD006649-tbl-0001">summary of findings Table 1</a>). These results did not change in a metaâanalysis including the studies that did not report data for the cancer subgroup (<a href="./references#CD006649-bbs2-0002" title="BÃ¼llerHR , GentM , GallusAS , GinsbergJ , PrinsMH , BaildonR , et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. New England Journal of Medicine1997;337(10):657-62. ">BÃ¼ller 1997 (COLOMBUS)</a>; <a href="./references#CD006649-bbs2-0003" title="DurouxP , NinetJ , BachetP , PrandoniP , RuolA , VigoM , et al. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study. Thrombosis and Haemostasis1991;65(3):251-6. ">Duroux 1991</a>; <a href="./references#CD006649-bbs2-0005" title="KoopmanMM , PrandoniP , PiovellaF , OckelfordPA , BrandjesDP , Van der MeerJ , et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. New England Journal of Medicine1996;334(11):682-7. ">Koopman 1996</a>; <a href="./references#CD006649-bbs2-0006" title="LevineM , GentM , HirshJ , LeclercJ , AndersonD , WeitzJ , et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine1996;334(11):677-81. ">Levine 1996</a>; <a href="./references#CD006649-bbs2-0013" title="SimonneauG , SorsH , CharbonnierB , PageY , LaabanJP , AzarianR , et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou heparine standard: evaluations dans l'embolie pulmonaire. New England Journal of Medicine1997;337(10):663-9. ">Simonneau 1997 (THESEE)</a>), and the studies published as abstracts (<a href="./references#CD006649-bbs2-0007" title="LindmarkerP , HolstromM , GranqvistS , JohnssonH , LocknerD . Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis1994;72(2):186-90. ">Lindmarker 1994</a>; <a href="./references#CD006649-bbs2-0008" title="LopaciukS , MeissnerAJ , FilipeckiS , ZawilskaK , SowierJ , CiesielskiL , et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thrombosis and Haemostasis1992;68(1):14-8. ">Lopaciuk 1992</a>) (RR 0.75, 95% CI 0.56 to 1.02). </p> </section> <section id="CD006649-sec-0062"> <h5 class="title">Recurrent venous thromboembolism</h5> <p>There were no data available for DVT or PE events separately. Metaâanalysis of three RCTs, including 422 participants, comparing LMWH to UFH found that LMWH may reduce VTE recurrence slightly (RR 0.69, 95% CI 0.27 to 1.76; RD 30 fewer per 1000, 95% CI 70 fewer to 73 more; low certainty evidence; <a href="./references#CD006649-fig-0005" title="">Analysis 1.2</a>) (<a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a>; <a href="./references#CD006649-bbs2-0009" title="MerliG , SpiroTE . Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191-202. ">Merli 2001</a>; <a href="./references#CD006649-bbs2-0011" title="PrandoniP , CarnovaliM , MarchioriA , Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164(10):1077. ">Prandoni 2004 (GALILEI)</a>). The I<sup>2</sup> value indicated moderate heterogeneity (I<sup>2</sup> = 46%). We judged the certainty of evidence for recurrent VTE to be low due to very serious imprecision (see <a href="./full#CD006649-tbl-0001">summary of findings Table 1</a>). There were no data available for bleeding outcomes, postphlebitic syndrome, quality of life, or thrombocytopenia. </p> </section> </section> <section id="CD006649-sec-0063"> <h4 class="title">Fondaparinux versus heparin</h4> <p>One study comparing fondaparinux with heparin (UFH and LMWH) found that fondaparinux: may increase mortality at three months (RR 1.25, 95% CI 0.86 to 1.81; RD 43 more per 1000, 95% CI 24 fewer to 139 more; low certainty evidence); may result in little to no difference in recurrent VTE (RR 0.93, 95% CI 0.56 to 1.54; RD 8 fewer per 1000, 95% CI 52 fewer to 63 more; low certainty evidence), may result in little to no difference in major bleeding (RR 0.82, 95% CI 0.40 to 1.66; RD 12 fewer per 1000, 95% CI 40 fewer to 44 more; low certainty evidence); and probably increases minor bleeding (RR 1.53, 95% CI 0.88 to 2.66; RD 42 more per 1000, 95% CI 10 fewer to 132 more; moderate certainty evidence) (<a href="./references#CD006649-bbs2-0014" title="BÃ¼llerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140:867-73. Van DoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusAG , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101:762-9. ">Van Doormaal 2009</a>). We judged the certainty of evidence for all outcomes, except minor bleeding, to be low due to very serious imprecision. We judged the evidence for minor bleeding to be moderate certainty due to serious imprecision (see <a href="./full#CD006649-tbl-0002">summary of findings Table 2</a>). </p> <p>There were no data available for postphlebitic syndrome, quality of life, or thrombocytopenia.</p> </section> <section id="CD006649-sec-0064"> <h4 class="title">Dalteparin versus tinzaparin</h4> <p>One study comparing dalteparin with tinzaparin found that dalteparin: may reduce mortality slightly (RR 0.86, 95% CI 0.43 to 1.73; RD 33 fewer per 1000, 95% CI 135 fewer to 173 more; low certainty evidence); may reduce VTE recurrence (RR 0.44, 95% CI 0.09 to 2.16; RD 47 fewer per 1000, 95% CI 77 fewer to 98 more; low certainty evidence); may increase major bleeding slightly (RR 2.19, 95% CI 0.20 to 23.42; RD 20 more per 1000, 95% CI 14 fewer to 380 more; low certainty evidence); and may reduce minor bleeding slightly (RR 0.82, 95% CI 0.30 to 2.21; RD 24 fewer per 1000, 95% CI 95 fewer to 164 more; low certainty evidence) (<a href="./references#CD006649-bbs2-0015" title="WellsPS , AndersonDR , RodgerMA , ForgieMA , FlorackP , TouchieD , et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Archives of Internal Medicine2005;165:733-8. ">Wells 2005</a>). We judged the certainty of evidence to be low for all outcomes due to very serious imprecision (see <a href="./full#CD006649-tbl-0003">summary of findings Table 3</a>). There were no data available for postphlebitic syndrome, quality of life, or thrombocytopenia. </p> <p>We did not create funnel plots for any of the outcomes as none of the analyses included 10 or more studies. Since none of the outcomes had a significant effect estimate, we did not conduct any sensitivity analysis to test the robustness of the results in relation to missing outcome data. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006649-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006649-sec-0065"></div> <section id="CD006649-sec-0066"> <h3 class="title" id="CD006649-sec-0066">Summary of main results</h3> <p>LMWH may reduce mortality and may reduce VTE recurrence slightly compared to UFH in the initial treatment of VTE in people with cancer. </p> </section> <section id="CD006649-sec-0067"> <h3 class="title" id="CD006649-sec-0067">Overall completeness and applicability of evidence</h3> <p>The completeness of the data was a major concern in this systematic review. First, of a total of 26 potentially eligible studies, we did not include 11 because the study authors did not report the required subgroup data for people with cancer. These 11 studies would have contributed 340 additional participants to the metaâanalysis (1615 are currently included). If the treatment effect from those studies was different from the reported effect, their exclusion from the metaâanalysis could have biased our results. Moreover, only three of the included studies reported cancer subgroup data for VTE recurrence and none reported cancer subgroup data for the bleeding outcomes. </p> </section> <section id="CD006649-sec-0068"> <h3 class="title" id="CD006649-sec-0068">Quality of the evidence</h3> <p>For the comparisons 'LMWH versus UFH' and 'dalteparin versus tinzaparin', we judged the certainty of evidence for all tested outcomes to be moderate due to very serious imprecision. For the comparison 'fondaparinux versus heparin', we judged the certainty of evidence to be low for all tested outcomes due to very serious imprecision, with the exception of minor bleeding, which had moderate certainty evidence. </p> </section> <section id="CD006649-sec-0069"> <h3 class="title" id="CD006649-sec-0069">Potential biases in the review process</h3> <p>Our systematic approach to searching for studies, selecting studies, and extracting data should have minimised the likelihood of missing relevant studies. The inclusion of different types of cancer in the same study precluded us from conducting the subgroup analyses to explore effect modifiers such as histological type and stage of cancer. A potential bias of our review might be the limitation of the electronic search strategy to people with cancer, while the data needed for this review came from studies not restricted to this subgroup. </p> </section> <section id="CD006649-sec-0070"> <h3 class="title" id="CD006649-sec-0070">Agreements and disagreements with other studies or reviews</h3> <p>Four previous systematic reviews compared the effects of LMWH and UFH on mortality in people with cancer and with VTE (<a href="./references#CD006649-bbs2-0112" title="ErkensPM , PrinsMH . Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews2010, Issue 9. Art. No: CD001100. [DOI: 10.1002/14651858.CD001100.pub3]">Erkens 2010</a>; <a href="./references#CD006649-bbs2-0046" title="GouldMK , DembitzerAD , DoyleRL , HastieTJ , GarberAM . Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Annals of Internal Medicine1999;130(10):800-9. ">Gould 1999</a>; <a href="./references#CD006649-bbs2-0117" title="HettiarachchiRJ , SmorenburgSM , GinsbergJ , LevineM , PrinsMH , BullerHR . Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thrombosis and Haemostasis1999;82:947-52.">Hettiarachchi 1999</a>; <a href="./references#CD006649-bbs2-0135" title="RobertsonL , JonesLE . Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD001100. [DOI: 10.1002/14651858.CD001100.pub4]">Robertson 2017</a>). We have limited our comparison to the two most recent systematic reviews. </p> <p>Erkens and colleagues conducted a Cochrane Review comparing fixedâdose LMWH versus UFH for treatment of acute VTE (<a href="./references#CD006649-bbs2-0112" title="ErkensPM , PrinsMH . Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews2010, Issue 9. Art. No: CD001100. [DOI: 10.1002/14651858.CD001100.pub3]">Erkens 2010</a>). In a subgroup analysis of people with cancer, they included 6 studies and 446 participants. The metaâanalysis found a significant reduction in mortality in the LMWH group compared to the UFH group at three months' followâup (OR 0.53, 95% CI 0.33 to 0.85). Erkens and colleagues did not include data from <a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a> for the outcome of mortality, and that explains the difference between our results. </p> <p>Robertson and colleagues also conducted a Cochrane Review evaluating the efficacy and safety of fixedâdose SC LMWH compared to adjustedâdose UFH (IV or SC) for the initial treatment of people with VTE. Similar to our finding, they found that LMWH resulted in a lower overall mortality compared with UFH (Peto OR 0.53, 95% CI 0.33 to 0.85; P = 0.009) (<a href="./references#CD006649-bbs2-0135" title="RobertsonL , JonesLE . Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD001100. [DOI: 10.1002/14651858.CD001100.pub4]">Robertson 2017</a>). Compared to our review, Robertson and colleagues did not include data from <a href="./references#CD006649-bbs2-0001" title="BreddinHK , Hach-WunderleV , NakovR , KakkarVV , Cortes Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. New England Journal of Medicine2001;344(9):626-31. ">Breddin 2001</a> and <a href="./references#CD006649-bbs2-0011" title="PrandoniP , CarnovaliM , MarchioriA , Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Archives of Internal Medicine2004;164(10):1077. ">Prandoni 2004 (GALILEI)</a>, and reported on Peto OR for the outcome of mortality, which may explain the slight discrepancy between their results and ours. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006649-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD006649-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study" data-id="CD006649-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies" data-id="CD006649-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH), Outcome 1: Mortality (3 months)" data-id="CD006649-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH), Outcome 1: Mortality (3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH), Outcome 2: Any recurrent venous thromboembolism (3 months)" data-id="CD006649-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH), Outcome 2: Any recurrent venous thromboembolism (3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fondaparinux versus heparin, Outcome 1: Mortality (3 months)" data-id="CD006649-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Fondaparinux versus heparin, Outcome 1: Mortality (3 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fondaparinux versus heparin, Outcome 2: Recurrent venous thromboembolism (3 months)" data-id="CD006649-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Fondaparinux versus heparin, Outcome 2: Recurrent venous thromboembolism (3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fondaparinux versus heparin, Outcome 3: Major bleeding (3 months)" data-id="CD006649-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Fondaparinux versus heparin, Outcome 3: Major bleeding (3 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Fondaparinux versus heparin, Outcome 4: Minor bleeding (3 months)" data-id="CD006649-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Fondaparinux versus heparin, Outcome 4: Minor bleeding (3 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dalteparin versus tinzaparin, Outcome 1: Mortality (3 months)" data-id="CD006649-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Dalteparin versus tinzaparin, Outcome 1: Mortality (3 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dalteparin versus tinzaparin, Outcome 2: Recurrent venous thromboembolism (3 months)" data-id="CD006649-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Dalteparin versus tinzaparin, Outcome 2: Recurrent venous thromboembolism (3 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dalteparin versus tinzaparin, Outcome 3: Major bleeding (3 months)" data-id="CD006649-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Dalteparin versus tinzaparin, Outcome 3: Major bleeding (3 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006649-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/urn:x-wiley:14651858:media:CD006649:CD006649-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Dalteparin versus tinzaparin, Outcome 4: Minor bleeding (3 months)" data-id="CD006649-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_t/tCD006649-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Dalteparin versus tinzaparin, Outcome 4: Minor bleeding (3 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/media/CDSR/CD006649/image_n/nCD006649-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006649-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Low molecular weight heparin compared to unfractionated heparin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Low molecular weight heparin compared to unfractionated heparin for initial treatment in people with cancer with VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cancer with venous thromboembolism (VTE)<br/><b>Setting:</b> inpatient/outpatient<br/><b>Intervention:</b> low molecular weight heparin (LMWH)<br/><b>Comparison:</b> unfractionated heparin (UFH) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/>Followâup</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with UFH</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with LMWH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>418<br/>(5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.40 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 fewer per 1000<br/>(101 fewer to 17 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent VTE<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>422<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/>(0.27 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 fewer per 1000<br/>(70 fewer to 73 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor bleeding â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postphlebitic syndrome â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (101 fewer per 1000) and potential harm (17 more per 1000), including 59 events in total.<br/><sup>b</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (70 fewer per 1000) and potential harm (73 more per 1000), including 34 events in total. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span>Â <span class="table-title">Low molecular weight heparin compared to unfractionated heparin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006649-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Fondaparinux compared to heparin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Fondaparinux compared to heparin for initial treatment in people with cancer with VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with cancer with VTE<br/><b>Setting:</b> inpatient/outpatient<br/><b>Intervention:</b> fondaparinux<br/><b>Comparison:</b> heparin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/>Followâup</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with heparin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with fondaparinux</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>477<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.25<br/>(0.86 to 1.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 more per 1000<br/>(24 fewer to 139 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent VTE<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>477<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/>(0.56 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/>(52 fewer to 63 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>477<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.40 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 fewer per 1000<br/>(40 fewer to 44 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>477<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.53<br/>(0.88 to 2.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 more per 1000<br/>(10 fewer to 132 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postphlebitic syndrome â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (24 fewer per 1000) and potential harm (139 more per 1000), including only 92 events in total.<br/><sup>b</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (52 fewer per 1000) and potential harm (63 moreÂ per 1000 ), including only 54 events in total.<br/><sup>c</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (40 fewer per 1000) and potential harm (44 moreÂ per 1000 ), including only 29 events in total.<br/><sup>d</sup>Downgraded by one level due to serious imprecision. Confidence interval suggests both potential no effect (10 fewer per 1000) and potential harm (132 moreÂ per 1000 ), including only 48 events in total. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Fondaparinux compared to heparin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006649-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Dalteparin compared to tinzaparin</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Dalteparin compared to tinzaparin for initial treatment in people with cancer with VTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> initial treatment in people with cancer with VTE<br/><b>Setting:</b> inpatient/outpatient<br/><b>Intervention:</b> dalteparin<br/><b>Comparison:</b> tinzaparin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes<br/>Followâup</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>â of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with tinzaparin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with dalteparin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>113<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.43 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/>(135 fewer to 173 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent VTE<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>113<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44<br/>(0.09 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 fewer per 1000<br/>(77 fewer to 98 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>113<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.19<br/>(0.20 to 23.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 more per 1000<br/>(14 fewer to 380 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Minor bleeding<br/>Followâup: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>113<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>ââââ<br/>Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.30 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 fewer per 1000<br/>(95 fewer to 164 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Postphlebitic syndrome â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia â not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>â</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (135 fewer per 1000 ) and potential harm (173 more per 1000 ), including 25 events among included participants.<br/><sup>b</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (77 fewer per 1000 ) and potential harm (98 more per 1000 ), including 7 events among included participants.<br/><sup>c</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (14 fewer per 1000 ) and potential harm (380 moreÂ per 1000 ), including 3 events among included participants.<br/><sup>d</sup>Downgraded by two levels due to very serious imprecision. Confidence interval suggests both potential benefit (95 fewer per 1000 ) and potential harm (164 more per 1000 ), including 14 events among included participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Dalteparin compared to tinzaparin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006649-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span>Â <span class="table-title">Glossary</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Term</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A priori</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Made before or without exam; not supported by factual study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assisting in the amelioration or cure of disease.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Process of hindering the clotting of blood, especially by treatment with an anticoagulant.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antithrombotic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Used against or tending to prevent thrombosis (clotting).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clotting.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis (DVT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Condition marked by the formation of a thrombus within a deep vein (such as of the leg or pelvis) that may be asymptomatic or be accompanied by symptoms (such as swelling and pain), and that is potentiallyâlife threatening if dislodgment of the thrombus results in pulmonary embolism. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fondaparinux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dalteparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tinzaparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haemostatic system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>System that shortens the clotting time of blood and stops bleeding.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by preventing the formation of fibrin. Two forms of heparin that are used as anticoagulant medications are: unfractionated heparin (UFH) and low molecular weight heparin (LMWH). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heterogeneity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality or state of being heterogeneous, i.e. incongruous. Statistical technique to check whether study results are consistent. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercoagulable state</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>State of excessive affinity to clotting.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impedance plethysmography</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Technique that measures the change in blood volume (venous blood volume as well as the pulsation of the arteries) for a specific body segment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kappa statistic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measure of degree of nonrandom agreement between observers, measurements of a specific categorical variable, or both. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spread of cancer cells from the initial or primary site of disease to another part of the body. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Parenteral nutrition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Practice of feeding a person intravenously, circumventing the gastrointestinal tract.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary embolism (PE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Embolism of a pulmonary artery or 1 of its branches that is produced by foreign matter and most often a blood clot originating in a vein of the leg or pelvis and that is marked by laboured breathing, chest pain, fainting, rapid heart rate, cyanosis, shock, and sometimes death. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Persistent decrease in the number of blood platelets that is often associated with haemorrhagic conditions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formation or presence of a blood clot within a blood vessel.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin K antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medications that are used for anticoagulation. Warfarin is a vitamin K antagonist. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warfarin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication that is a vitamin K antagonist used for anticoagulation.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ximelagatran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticoagulant medication.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span>Â <span class="table-title">Glossary</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/full#CD006649-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006649-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mortality (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.40, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Any recurrent venous thromboembolism (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.27, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>Â <span class="table-title">Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006649-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Fondaparinux versus heparin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Mortality (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.86, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Recurrent venous thromboembolism (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.56, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Major bleeding (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.40, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Minor bleeding (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.88, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>Â <span class="table-title">Fondaparinux versus heparin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006649-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span>Â <span class="table-title">Dalteparin versus tinzaparin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Mortality (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.43, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Recurrent venous thromboembolism (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.09, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Major bleeding (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.20, 23.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Minor bleeding (3 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (MâH, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.30, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>Â <span class="table-title">Dalteparin versus tinzaparin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006649.pub8/references#CD006649-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006649.pub8&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006649-note-0016">EspaÃ±ol</a> </li> <li class="section-language"> <a class="" href="fa#CD006649-note-0013">ÙØ§Ø±Ø³Û</a> </li> <li class="section-language"> <a class="" href="fr#CD006649-note-0015">FranÃ§ais</a> </li> <li class="section-language"> <a class="" href="ja#CD006649-note-0012">æ¥æ¬èª</a> </li> <li class="section-language"> <a class="" href="ko#CD006649-note-0010">íêµ­ì´</a> </li> <li class="section-language"> <a class="" href="ms#CD006649-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006649-note-0014">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD006649-note-0009">PortuguÃªs</a> </li> <li class="section-language"> <a class="" href="ru#CD006649-note-0008">Ð ÑÑÑÐºÐ¸Ð¹</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006649-note-0006">ç®ä½ä¸­æ</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006649-note-0007">ç¹é«ä¸­æ</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright Â© 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">Â Â Facebook</a> <a class="a2a_button_x share-button">Â Â X(Twitter)</a> <a class="a2a_button_whatsapp share-button">Â Â WhatsApp</a> <a class="a2a_dd share-button">Â Â View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006649\x2epub8"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006649\x2epub8"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006649\x2epub8"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006649\x2epub8\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006649\x2epub8"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006649.pub8&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006649.pub8';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">EspaÃ±ol</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">ÙØ§Ø±Ø³Û</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">FranÃ§ais</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">à¤¹à¤¿à¤¨à¥à¤¦à¥</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">æ¥æ¬èª</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">íêµ­ì´</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">PortuguÃªs</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Ð ÑÑÑÐºÐ¸Ð¹</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">RomÃ¢nÄ</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">à®¤à®®à®¿à®´à¯</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">à¸ à¸²à¸©à¸²à¹à¸à¸¢</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">ç¹é«ä¸­æ</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">ç®ä½ä¸­æ</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006649.pub8/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006649.pub8/full/es">EspaÃ±ol</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006649.pub8%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717867513"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006649.pub8/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717867516"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006649.pub8/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc267fd569377',t:'MTc0MDcxNzg2Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 